Notice: This company has been marked as potentially delisted and may not be actively trading. Leisure Acquisition (LACQ) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends LACQ vs. INDP, AEZS, KPRX, AYTU, MBIO, CDT, RDHL, VCNX, ENSC, and VINCShould you be buying Leisure Acquisition stock or one of its competitors? The main competitors of Leisure Acquisition include Indaptus Therapeutics (INDP), Aeterna Zentaris (AEZS), Kiora Pharmaceuticals (KPRX), Aytu BioPharma (AYTU), Mustang Bio (MBIO), Conduit Pharmaceuticals (CDT), RedHill Biopharma (RDHL), Vaccinex (VCNX), Ensysce Biosciences (ENSC), and Vincerx Pharma (VINC). Leisure Acquisition vs. Indaptus Therapeutics Aeterna Zentaris Kiora Pharmaceuticals Aytu BioPharma Mustang Bio Conduit Pharmaceuticals RedHill Biopharma Vaccinex Ensysce Biosciences Vincerx Pharma Indaptus Therapeutics (NASDAQ:INDP) and Leisure Acquisition (NASDAQ:LACQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations. Do analysts recommend INDP or LACQ? Indaptus Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 717.31%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Indaptus Therapeutics is more favorable than Leisure Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Leisure Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, INDP or LACQ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.42M-$1.71-0.61Leisure AcquisitionN/AN/A$4.31MN/AN/A Is INDP or LACQ more profitable? Leisure Acquisition's return on equity of 30.17% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -177.27% -141.06% Leisure Acquisition N/A 30.17%6.14% Do institutionals & insiders have more ownership in INDP or LACQ? 7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 56.7% of Leisure Acquisition shares are held by institutional investors. 29.5% of Indaptus Therapeutics shares are held by insiders. Comparatively, 39.6% of Leisure Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer INDP or LACQ? Indaptus Therapeutics received 13 more outperform votes than Leisure Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33%Leisure AcquisitionN/AN/A Does the media prefer INDP or LACQ? In the previous week, Indaptus Therapeutics had 2 more articles in the media than Leisure Acquisition. MarketBeat recorded 2 mentions for Indaptus Therapeutics and 0 mentions for Leisure Acquisition. Indaptus Therapeutics' average media sentiment score of 0.54 beat Leisure Acquisition's score of -1.38 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Indaptus Therapeutics Positive Leisure Acquisition Negative Which has more volatility and risk, INDP or LACQ? Indaptus Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Leisure Acquisition has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500. SummaryIndaptus Therapeutics beats Leisure Acquisition on 7 of the 12 factors compared between the two stocks. Ad Porter & CompanyThe Great AI-Energy CollisionThe biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector. Get the full story here, while you still can. Get Leisure Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for LACQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LACQ vs. The Competition Export to ExcelMetricLeisure AcquisitionPharmaceutical Preparations Industry SectorNASDAQ ExchangeMarket Cap$3.41M$6.70B$1.98B$8.88BDividend YieldN/A8.07%15.23%4.07%P/E RatioN/A11.3410.8317.98Price / SalesN/A247.275,932.8467.54Price / Cash20.0322.52123.7034.49Price / Book-2.885.521.284.92Net Income$4.31M$153.34M-$716.83M$225.84M Leisure Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LACQLeisure AcquisitionN/A$0.55+14.6%N/A-45.6%$3.41MN/A0.00N/ANegative NewsGap UpHigh Trading VolumeINDPIndaptus Therapeutics2.9818 of 5 stars$1.02+2.0%$8.50+733.3%-51.0%$10.40MN/A0.006News CoverageGap DownAEZSAeterna ZentarisN/A$5.72+5.9%N/A-62.9%$10.26M$2.37M-0.3820Analyst ForecastNews CoverageGap UpKPRXKiora Pharmaceuticals2.733 of 5 stars$3.39+0.6%$10.00+195.0%-32.9%$10.17MN/A0.0010AYTUAytu BioPharma0.8143 of 5 stars$1.63-0.3%N/A-37.2%$9.99M$81M0.00160High Trading VolumeMBIOMustang Bio1.4905 of 5 stars$0.21flat$2.00+875.1%-88.0%$9.80MN/A-0.13100CDTConduit PharmaceuticalsN/A$0.09-9.4%N/A-95.1%$9.69MN/A0.003Gap DownRDHLRedHill Biopharma0.5305 of 5 stars$7.34+8.3%N/A-96.0%$9.40M$3.71M0.00210VCNXVaccinexN/A$3.55-1.9%N/A-72.1%$9.23M$570,000.00-0.0740Gap UpENSCEnsysce Biosciences0.0374 of 5 stars$0.47+9.3%N/A-45.6%$9.20M$2.23M0.0010News CoverageGap UpVINCVincerx Pharma2.8493 of 5 stars$0.27+7.1%$2.00+640.7%-65.1%$9.06MN/A0.0060 Related Companies and Tools Related Companies INDP Alternatives AEZS Alternatives KPRX Alternatives AYTU Alternatives MBIO Alternatives CDT Alternatives RDHL Alternatives VCNX Alternatives ENSC Alternatives VINC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LACQ) was last updated on 11/26/2024 by MarketBeat.com Staff From Our PartnersA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | Sponsored140% Yields From Stocks Like Tesla? Here's How (Black Friday Special)140% Dividends from stocks like Tesla? Discover How for Just $9! For Black Friday, get the full details of ...Investors Alley | Sponsored9 hidden AI stocks set to thrive in Trump’s new eraAI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be wor...StockEarnings | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored❗[Investor Alert] Under-the-Radar TechWhile most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One c...TuneGO | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leisure Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leisure Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.